-
公开(公告)号:US20240417677A1
公开(公告)日:2024-12-19
申请号:US18745228
申请日:2024-06-17
Applicant: University of Saskatchewan
Inventor: Bishnu Acharya , Nirpesh Dhakal
Abstract: The disclosure relates to canola meal extracts (CMEs), and methods of making said CMEs. Also provided herein are compositions and culture media comprising said CMEs and use of said CMEs, compositions, and culture media for microbial fermentation across a broad class of microbes. The disclosure further relates to use of said CMEs and compositions as a partial or complete replacement for other organic extracts such as yeast extract.
-
公开(公告)号:US20240197865A1
公开(公告)日:2024-06-20
申请号:US18556668
申请日:2022-04-22
Applicant: University of Saskatchewan
Inventor: Sylvia Van Den Hurk , Volker Gerdts , Robert Brownlie , Ravendra Garg
IPC: A61K39/295 , A61K39/00 , A61K39/39 , A61P37/04 , C07K14/005
CPC classification number: A61K39/295 , A61K39/39 , A61P37/04 , C07K14/005 , A61K2039/55511 , A61K2039/55516 , A61K2039/55555 , A61K2039/55561 , A61K2039/6018 , A61K2039/70 , C12N2760/18522 , C12N2760/18534 , C12N2760/18622 , C12N2760/18634
Abstract: The present invention provides immunogenic chimeric respiratory syncytial virus (RSV)-parainfluenza virus type 3 (PIV3) compounds and associated compositions, along with methods of treating, preventing and/or diagnosing RSV- and PIV3-related disorders.
-
公开(公告)号:US11819019B2
公开(公告)日:2023-11-21
申请号:US16768807
申请日:2018-12-03
Applicant: University of Saskatchewan
Inventor: Francois Eudes , Jaswant Singh , Kosala Rajapaksha , Muhammad Anzar , Gregg P. Adams
CPC classification number: A01N1/0221 , A01N1/0278 , A01N1/0284 , C12N5/061
Abstract: This disclosure provides a preserving composition comprising a cholesterol: carrier complex, optionally a cholesterol:cyclodextrin complex (CC complex) and/or a cell permeable antioxidant peptide and a biological buffer and optionally a cryprotectant, wherein the preserving composition is optionally substantially free of animal phospholipid, animal protein and/or animal lipoprotein. The disclosure also provides methods for the use of the preserving composition in cryopreservation of semen or sperm cells. Also provided is a kit comprising the preserving composition having a CC complex, a biological buffer, a cryoprotectant, a carbohydrate, a pH stabilizer, an antibiotic or antibiotic cocktail and/or a cell permeable anti-oxidant peptide.
-
公开(公告)号:US11412953B2
公开(公告)日:2022-08-16
申请号:US17008096
申请日:2020-08-31
Applicant: UNIVERSITY OF SASKATCHEWAN
Inventor: Darryl Adamko , Anas El-Aneed
Abstract: Described are methods and uses employing metabolomic data to diagnose an asthma disease state or a Chronic Obstructive Pulmonary Disease (COPD) state. Further described are methods of uses of employing metabolomic data to distinguish between asthma and COPD. In particular, urinary metabolomic profiles are employed to enable differential diagnosis of asthma and COPD.
-
公开(公告)号:US20220195473A1
公开(公告)日:2022-06-23
申请号:US17691933
申请日:2022-03-10
Inventor: Jonathan E. Page , Steve Gagne
Abstract: Nucleic acid molecules encoding polypeptides having polyketide synthase activity have been identified and characterized. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds in organisms. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.
-
公开(公告)号:US20220154209A1
公开(公告)日:2022-05-19
申请号:US17392164
申请日:2021-08-02
Applicant: University of Saskatchewan
Inventor: Suresh K. TIKOO , Xin ZHAO
IPC: C12N15/86 , A61K35/761 , A61K39/00 , A61K39/02 , A61K39/12
Abstract: The present application provided defective bovine adenovirus (BAV) vectors that lack pV function. Cell lines and methods of preparing such vectors are provided. In addition, the invention provides methods of treating a disease or disorder with a defective BAV lacking pV function as well as vaccine comprising a defective BAV lacking pV function.
-
公开(公告)号:US11124575B2
公开(公告)日:2021-09-21
申请号:US16487673
申请日:2018-02-22
Inventor: Sachdev Sidhu , Shane Miersch , Clarence Ronald Geyer
Abstract: An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.
-
公开(公告)号:US20210244807A1
公开(公告)日:2021-08-12
申请号:US17156477
申请日:2021-01-22
Applicant: University of Saskatchewan , Kenya Agriculture and Livestock Research Organization (KALRO) , International Livestock Research Institute (ILRI)
Inventor: Andrew POTTER , Volker GERDTS , Jose PEREZ-CASAL , Yejun WANG , Hezron WESONGA , Reuben SOI , Jan NAESSENS , Joerg JORES
Abstract: Immunogenic proteins comprising Mycoplasma mycoides subsp. mycoides and M. mycoides subsp. capri proteins, encoding polynucleotides, a method for producing said proteins, and use of compositions to prevent M. mycoides subsp. mycoides infections are disclosed.
-
公开(公告)号:US20210228511A1
公开(公告)日:2021-07-29
申请号:US17156167
申请日:2021-01-22
Applicant: University of Saskatchewan
Inventor: Juan P. Ianowski , Julian S. Tam , Xiaojie Luan , Veronica A. Campanucci
IPC: A61K31/165 , A61K33/14 , A61K9/00 , A61K31/05
Abstract: The present application relates to a method of increasing the volume of an airway surface liquid (ASL) layer and/or increasing mucociliary clearance in a subject. For example, the application relates the use of one or more neuronal agonists such as menthol and/or capsaicin, in combination with hypertonic saline (HTS) or isotonic saline (ITS) for increasing the volume of airway surface liquid (ASL) and/or increasing mucociliary clearance or for treatment of a disease, disorder or condition treatable by increasing the volume of an ASL layer and/or increasing mucociliary clearance. For example, the disease, disorder or condition is cystic fibrosis or a non-cystic fibrosis respiratory disease, disorder or condition such as non-cystic fibrosis bronchiectasis.
-
公开(公告)号:US20210219410A1
公开(公告)日:2021-07-15
申请号:US17250302
申请日:2019-07-04
Inventor: Sylvain FOURMAUX , Jean-Claude KIEFFER , Emil HALLIN
IPC: H05G2/00 , G01N23/041 , G01N33/00
Abstract: A X-ray source, comprising a laser, of a pulse duration of at most 40 fs, instantaneous power of at least about 80TW, a pulse repetition rate of at least 1 Hz; an optical compressor spectrally shaping the laser beam; focusing optics in the range between f#10 and f#15; and a gas target of electron density after ionization by the laser beam in a range between 1018 cm3 and 1019 cm−3; wherein the focusing optics focuses the laser beam in the gas target, and interaction of the focused laser beam with the gas target generates an X-ray beam, with a focused laser amplitude a0, given by a0=0.855 [IL (1018W/cm2)λL,2 (μm)]1/2, where IL is the on-target laser intensity and λL is the laser wavelength, of at least 2 and a P/Pc ratio value of at least 20, with P being the beam power and Pc a critical power given by Pc=17 (nc/n) GW where n is the electron density and nc is a critical electron density at which the plasma acts as a mirror reflecting the laser beam.
-
-
-
-
-
-
-
-
-